Nectin‐2 in ovarian cancer: how is it expressed and what might be its functional role?
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: Cancer Science (2019) 110:6, 1872– 1882. https://doi.org/10.1111/cas.13992
- Ereignis
-
Veröffentlichung
- (wo)
-
Würzburg
- (wer)
-
Universität Würzburg
- (wann)
-
2020
- Urheber
-
Bekes, Inga
Löb, Sanja
Holzheu, Iris
Janni, Wolfgang
Baumann, Lisa
Wöckel, Achim
Wulff, Christine
- URN
-
urn:nbn:de:bvb:20-opus-202748
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:46 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Bekes, Inga
- Löb, Sanja
- Holzheu, Iris
- Janni, Wolfgang
- Baumann, Lisa
- Wöckel, Achim
- Wulff, Christine
- Universität Würzburg
Entstanden
- 2020
Ähnliche Objekte (12)
Nectin‐2 in ovarian cancer: How is it expressed and what might be its functional role?
Does VEGF facilitate local tumor growth and spread into the abdominal cavity by suppressing endothelial cell adhesion, thus increasing vascular peritoneal permeability followed by ascites production in ovarian cancer?
Ovarian cancer
Ovarian cancer
Ovarian cancer proteomics
Are circulating tumor cells (CTCs) ready for clinical use in breast cancer? An overview of completed and ongoing trials using CTCs for clinical treatment decisions
Ovarian cancer-cell pericellular hyaluronan deposition negatively impacts prognosis of ovarian cancer patients
Intraperitoneal therapy for ovarian cancer
Current treatment of Ovarian Cancer
Rationale and description of a lifestyle intervention programme to achieve moderate weight loss in women with non-metastatic breast cancer: the lifestyle intervention part of the SUCCESS C study
Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers
Ovarian cancer : proceedings of the Internat. Symposium on Ovarian Cancer, Birmingham, 24 - 25 September 1979
Nectin‐2 in ovarian cancer: How is it expressed and what might be its functional role?
Does VEGF facilitate local tumor growth and spread into the abdominal cavity by suppressing endothelial cell adhesion, thus increasing vascular peritoneal permeability followed by ascites production in ovarian cancer?
Ovarian cancer
Ovarian cancer
Ovarian cancer proteomics
Are circulating tumor cells (CTCs) ready for clinical use in breast cancer? An overview of completed and ongoing trials using CTCs for clinical treatment decisions
Ovarian cancer-cell pericellular hyaluronan deposition negatively impacts prognosis of ovarian cancer patients
Intraperitoneal therapy for ovarian cancer
Current treatment of Ovarian Cancer
Rationale and description of a lifestyle intervention programme to achieve moderate weight loss in women with non-metastatic breast cancer: the lifestyle intervention part of the SUCCESS C study
Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers
Ovarian cancer : proceedings of the Internat. Symposium on Ovarian Cancer, Birmingham, 24 - 25 September 1979
Nectin‐2 in ovarian cancer: How is it expressed and what might be its functional role?
Does VEGF facilitate local tumor growth and spread into the abdominal cavity by suppressing endothelial cell adhesion, thus increasing vascular peritoneal permeability followed by ascites production in ovarian cancer?
Ovarian cancer
Ovarian cancer
Ovarian cancer proteomics
Are circulating tumor cells (CTCs) ready for clinical use in breast cancer? An overview of completed and ongoing trials using CTCs for clinical treatment decisions
Ovarian cancer-cell pericellular hyaluronan deposition negatively impacts prognosis of ovarian cancer patients
Intraperitoneal therapy for ovarian cancer
Current treatment of Ovarian Cancer
Rationale and description of a lifestyle intervention programme to achieve moderate weight loss in women with non-metastatic breast cancer: the lifestyle intervention part of the SUCCESS C study
Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers